- Home
- PHAT vs AXG Comparison
PHAT vs AXG Comparison
Compare PHAT & AXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- AXG
- Stock Information
- Founded
- PHAT 2018
- AXG 2021
- Country
- PHAT United States
- AXG Hong Kong
- Employees
- PHAT N/A
- AXG N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- AXG Investment Bankers/Brokers/Service
- Sector
- PHAT Health Care
- AXG Finance
- Exchange
- PHAT Nasdaq
- AXG Nasdaq
- Market Cap
- PHAT 769.0M
- AXG 692.6M
- IPO Year
- PHAT 2019
- AXG 2023
- Fundamental
- Price
- PHAT $13.55
- AXG $3.54
- Analyst Decision
- PHAT Strong Buy
- AXG
- Analyst Count
- PHAT 5
- AXG 0
- Target Price
- PHAT $17.60
- AXG N/A
- AVG Volume (30 Days)
- PHAT 1.3M
- AXG 1.1M
- Earning Date
- PHAT 10-30-2025
- AXG 06-30-2025
- Dividend Yield
- PHAT N/A
- AXG N/A
- EPS Growth
- PHAT N/A
- AXG N/A
- EPS
- PHAT N/A
- AXG N/A
- Revenue
- PHAT $147,190,000.00
- AXG $3,316,000.00
- Revenue This Year
- PHAT $213.65
- AXG $28.53
- Revenue Next Year
- PHAT $91.41
- AXG $54.60
- P/E Ratio
- PHAT N/A
- AXG N/A
- Revenue Growth
- PHAT 460.30
- AXG N/A
- 52 Week Low
- PHAT $2.21
- AXG $2.91
- 52 Week High
- PHAT $19.50
- AXG $4.17
- Technical
- Relative Strength Index (RSI)
- PHAT 58.66
- AXG N/A
- Support Level
- PHAT $13.02
- AXG N/A
- Resistance Level
- PHAT $16.08
- AXG N/A
- Average True Range (ATR)
- PHAT 1.05
- AXG 0.00
- MACD
- PHAT -0.02
- AXG 0.00
- Stochastic Oscillator
- PHAT 44.88
- AXG 0.00
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About AXG Solowin Holdings Class A Ordinary Share
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.